Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Effects of KDT501 on Metabolic Features in Insulin Resistant Subjects
KDT501 is an orally administered product designed to help control impaired glucose and
insulin regulation in patients with insulin resistance. Nonclinical studies demonstrate
agonist activity of KDT501 at the G-protein coupled receptor 120 as well as other G-protein
receptors. Nonclinical studies have also documented the ability of KDT501 to improve insulin
sensitivity and glucose regulation as well as reduce proinflammatory signals. These
properties combined with antihyperglycemic activity and modest, partial agonist effect of
KDT501 at the peroxisome proliferator-activated receptor-gamma (PPARĪ³) receptor suggests an
atypical and pleiotropic mechanism of action for KDT501.
Following providing informed consent, potential subjects will undergo screening procedures to
ensure that they meet all inclusion and exclusion criteria. Following registration on study,
subjects will undergo baseline pretreatment studies, including two abdominal fat biopsies,
one taken after cold challenge, as well as determination of resting metabolic rate, a 4 hour
lipid tolerance test, and a 2 hour euglycemic clamp study. All pretreatment studies in
registered subjects will be performed within 7 days prior to initiating therapy. On the first
day of treatment (Day 0), subjects will take the first 600 mg dose of KDT501 in the clinic,
followed by serum pharmacokinetic (PK) samples being obtained every hour for 6 hours after
dosing. Subjects will then continue dosing as an outpatient, 600 mg po twice daily. All doses
will be taken with meals (breakfast and dinner). On Day 7, subjects will return to the clinic
to undergo safety and laboratory assessments, including PK. On Days 14 and 21, subjects will
again return to the clinic to undergo safety and laboratory assessments. On Day 17 subjects
will return to the clinic for PK studies, as noted below. Treatment in all subjects will end
on Day 28. Rapid PK assessment of drug exposure, defined as AUC0-12h, will be performed
following PK samples drawn at Time 0, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, and 12h on both Days 7
and 17. On Days 11 and 21 (±1day), based on the KDT501 drug exposure level, the subject will
be provided instructions on dose adjustments of KDT501. The maximum allowed KDT501 exposure
ceiling for all subjects enrolled is AUC0-12h = 22,500ng-hr/mL.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
| Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
| Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
| Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
| Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
| Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
| Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
| Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
| Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
| Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
| Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
| Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
| Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
| Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
| Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
| Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
| Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
| Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |